None
Conditions
Interventions
The remimazolam besylate group (Group R) and the propofol group (Group P):Group R (Remimazolam):
- Induction: 0.4 mg/kg IV bolus
- Maintenance: Continuous infusion at 1 mg/kg/h
The propofol group (Group P):Group P (Propofol):
- Induction: 2.0-2.5 mg/kg IV bolus
- Maintenance: Continuous infusion at 4-6 mg/kg/h
Sponsors
The Sixth Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 60 years; 2) Patients undergoing hysteroscopic surgery under general anesthesia; 3) ASA physical status = III; 4) Body mass index (BMI) between 18 kg/m^2 and 30 kg/^2; 5) Fully informed about the study and voluntarily participating, with signed informed consent obtained from either the patient or their legally authorized representative.
Exclusion criteria
Exclusion criteria: 1) Severe systemic diseases (ASA physical status = IV); 2) Cognitive dysfunction or psychiatric/psychological disorders; 3) Use of other investigational drugs within 1 month prior to enrollment or current participation in other clinical trials; 4) Uncooperative patients, those lost to follow-up after discharge, or refusal to participate in follow-up; 5) Other conditions deemed by clinicians as unsuitable for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Non-invasive blood pressure ;Pulse oxygen saturation;Heart rate;Bispectral Index Score;Plasma concentration of remimazolam besylate;Plasma concentration of propofol; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body temperature; | — |
Countries
China
Contacts
Public ContactMeng Fanyou
The Sixth Affiliated Hospital of Harbin Medical UniversityLC
Outcome results
None listed